CARDIZEM LA (diltiazem hydrochloride)
Cardizem LA is a medication used to manage high blood pressure and chronic stable angina. It helps patients lower their blood pressure, which reduces the risk of serious cardiovascular events like strokes and heart attacks. For those with chest pain, it is used to improve exercise tolerance. This drug can be used alone or in combination with other medications to help patients reach their cardiovascular health goals.
How CARDIZEM LA Works
This drug works by blocking calcium ions from entering the cells of the heart and blood vessel muscles. This action relaxes the vascular smooth muscle and lowers peripheral resistance, which effectively reduces blood pressure. In cases of angina, it dilates the coronary arteries and lowers the heart's oxygen demand by reducing heart rate and systemic pressure during physical activity.
Details
- Status
- Prescription
- First Approved
- 2003-02-06
- Routes
- ORAL
- Dosage Forms
- TABLET, EXTENDED RELEASE
CARDIZEM LA Approval History
What CARDIZEM LA Treats
2 indicationsCARDIZEM LA is approved for 2 conditions since its original approval in 2003. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypertension
- Angina
CARDIZEM LA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in CARDIZEM LA's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications CARDIZEM LA treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to CARDIZEM LA
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
2 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07456852 | MC250411 NCI-2026-01065, MC250411 | Ph 1, Ph 2 | not yet recruiting | Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy |
| NCT04777045 EDIT-CMD | NL67497.091.19 2018-003518-41 | Ph 3 | active not recruiting | Efficacy of Diltiazem to Improve Coronary Microvascular Dysfunction: a Randomized Clinical Trial |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CARDIZEM LA FDA Label Details
Indications & Usage
FDA Label (PDF)CARDIZEM LA is indicated for the treatment of Hypertension; Angina.
Track CARDIZEM LA with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.